Lu J - Search Results

1

Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.

Wu Z, Zhang L, Peng J, Xu S, Zhou L, Lin Y, Wang Y, Lu J, Yin W, Lu J. Wu Z, et al. Among authors: lu j. Cancer Biol Ther. 2019;20(6):941-947. doi: 10.1080/15384047.2019.1583533. Epub 2019 Mar 13. Cancer Biol Ther. 2019. PMID: 30866717 Free PMC article.

2

Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.

Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM. Li HC, et al. Among authors: lu js. Breast Cancer Res Treat. 2004 Nov;88(1):75-85. doi: 10.1007/s10549-004-1200-8. Breast Cancer Res Treat. 2004. PMID: 15538048

3

[Clinicopathological significance of aromatase expression in breast cancers].

Lu JS, Li HC, Cao DC, Di GH, Wu J, Shen KW, Shen ZZ, Shao ZM. Lu JS, et al. Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1318-21. Zhonghua Wai Ke Za Zhi. 2006. PMID: 17217816 Chinese.

4

Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.

Yu KD, Liu GY, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM. Yu KD, et al. Among authors: lu js. Breast. 2007 Jun;16(3):307-15. doi: 10.1016/j.breast.2006.12.011. Epub 2007 Feb 12. Breast. 2007. PMID: 17293115

5

[Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].

Fan J, Lu JS, Yin WJ, Lei W, Wu FY, Wu J, Hou YF, Li DQ, Di GH, Shen ZZ, Shao ZM. Fan J, et al. Among authors: lu js. Zhonghua Zhong Liu Za Zhi. 2006 Dec;28(12):886-9. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17533736 Chinese.

6

[Clinico-pathological features of ER+/PR+ and ER+/PR- breast tumors: a comparative study of 5211 cases].

Zhou LH, Yin WJ, Lu JS, DI GH, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM. Zhou LH, et al. Among authors: lu js. Zhonghua Yi Xue Za Zhi. 2007 Oct 23;87(39):2764-7. Zhonghua Yi Xue Za Zhi. 2007. PMID: 18167267 Chinese.

7

ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.

Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, Di GH, Shen ZZ, Shao ZM. Fan J, et al. Among authors: lu js. J Cancer Res Clin Oncol. 2008 Aug;134(8):883-90. doi: 10.1007/s00432-008-0354-x. Epub 2008 Feb 9. J Cancer Res Clin Oncol. 2008. PMID: 18264725

8

Time-varying pattern of recurrence risk for Chinese breast cancer patients.

Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Yin W, et al. Among authors: lu j. Breast Cancer Res Treat. 2009 Apr;114(3):527-35. doi: 10.1007/s10549-008-0022-5. Epub 2008 Apr 19. Breast Cancer Res Treat. 2009. PMID: 18425576

9

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM. Yu KD, et al. Among authors: lu js. J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17. J Cancer Res Clin Oncol. 2008. PMID: 18488249

10

Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients.

Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM. Yin WJ, et al. Among authors: lu js. Breast Cancer Res Treat. 2009 May;115(2):325-33. doi: 10.1007/s10549-008-0096-0. Epub 2008 Jun 18. Breast Cancer Res Treat. 2009. PMID: 18563552

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34,041 results

Search Page

Filters